Do you want to read an article? Please log in or register.
DESTINY-Breast12: T-DXd proved effective in patients with HER2-positive metastatic breast cancer with or without brain metastases
Breast Cancer
ESMO 2024
Related content
ASCO 2024
Breast Cancer
DESTINY-Breast06: T-DXd significantly improves PFS in HER2-low and HER2-ultralow metastatic breast cancer
COMMENTED
Breast Cancer
A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
André F, Cortés J, Curigliano G, Modi S, Li W, Park YH, Chung WP, Kim SB, Yamashita T, Pedrini JL, Im SA, Tseng LM, Harbeck N, Krop I, Nakatani S, Tecson K, Ashfaque S, Egorov A, Hurvitz SA
doi: 10.1016/j.annonc.2024.08.2347
Breast Cancer
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol
Fehm T, Cottone F, Dunton K, André F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB
doi: 10.1016/S1470-2045(24)00128-1
ASCO 2024
Breast Cancer
TROPION-Breast01: PROs data reinforce Dato-DXd as a potential new therapeutic option for HR-positive, HER2-negative metastatic breast cancer
Breast Cancer
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
Eur J Cancer
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L
doi: 10.1016/j.ejca.2024.115113
ASCO 2024
Breast Cancer
NATALEE: Ribociclib plus NSAI is effective and tolerable in patients with high-risk node-negative HR-positive, HER2-negative early breast cancer
ESMO 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Dato-DXd benefits patients with advanced non-squamous NSCLC with or without brain metastases
Breast Cancer
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis
Cancer Treat Rev
Michelon I, Castro CER, Madeira T, Dacoregio MI, Stecca C, Soares LR, Saeed A, Vilbert M, Cavalcante L
doi: 10.1016/j.ctrv.2025.102882
SABCS 2024
Breast Cancer